The lead product in development, ProCervix, is a bivalent vaccine for individuals infected with the most common oncogenic genotypes, HPV 16 and/or HPV 18. A phase I/II clinical trial with ProCervix is scheduled for 2010.

The second product candidate is also a therapeutic HPV vaccine  that is currently in research stage and will target patients with a different medical need.